BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 316368)

  • 1. Significance of the 48-hour plasma level in high-dose methotrexate regimens.
    Perez C; Wang YM; Sutow WW; Herson J
    Cancer Clin Trials; 1978; 1(2):107-11. PubMed ID: 316368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of hydration on plasma concentrations of methotrexate in patients with osteosarcoma treated with high doses of methotrexate].
    Ferrari S; Orlandi M; Avella M; Caldora P; Ferraro A; Ravazzolo G; Bacci G
    Minerva Med; 1992 May; 83(5):289-93. PubMed ID: 1589134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma.
    Wang YM; Sutow WW; Romsdahl MM; Perez C
    Cancer Treat Rep; 1979 Mar; 63(3):405-10. PubMed ID: 284845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The influence of liver and renal functions on the changes in serum methotrexate (MTX) level in high-dose MTX therapy].
    Sato T; Nakanishi K; Takahashi M; Sato K; Miura T; Kuzuya T; Mizuno M
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2375-9. PubMed ID: 2260874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of overall toxicity of high-dosage methotrexate regimens.
    Perez C; Sutow WW; Wang YM; Herson J
    Med Pediatr Oncol; 1979; 6(3):219-28. PubMed ID: 314042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity.
    Stoller RG; Hande KR; Jacobs SA; Rosenberg SA; Chabner BA
    N Engl J Med; 1977 Sep; 297(12):630-4. PubMed ID: 302412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II clinical trial with high-dose methotrexate therapy and citrovorum factor rescue.
    Isacoff WH; Eilber F; Tabbarah H; Klein P; Dollinger M; Lemkin S; Sheehy P; Cone L; Rosenbloom B; Sieger L; Block JB
    Cancer Treat Rep; 1978 Sep; 62(9):1295-304. PubMed ID: 356984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of severe side effects of high-dose methotrexate in osteosarcoma].
    Umeda T; Takada N; Hodaka E; Endoh F; Ishii T
    Gan To Kagaku Ryoho; 1984 Feb; 11(2):285-94. PubMed ID: 6582805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Moderate dose methotrexate with citrovorum factor rescue therapy in the treatment of head and neck cancer].
    Inuyama Y; Hiroto I; Taketa C; Horiuchi M; Mashino S; Fujii M; Matsuura S; Satake B; Takeoda S; Nishijima W; Okuda M; Sakaguchi K; Tanigaito Y; Imakirei M; Konno T; Hirokawa T; Takada K; Ono I; Saitoh H; Takemiya S; Shimada F; Omura K; Miyake H; Fujii K; Kawabe Y; Kondoh T; Komiyama S; Yanagida T; Matsumura Y; Hirano M; Araki S
    Gan To Kagaku Ryoho; 1982 Dec; 9(12):2193-200. PubMed ID: 6764099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma.
    Pitman SW; Frei E
    Cancer Treat Rep; 1977 Jul; 61(4):695-701. PubMed ID: 18282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
    Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
    Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A device for rapid elevation of plasma methotrexate (MTX) concentration and its maintenance in high-dose MTX therapy].
    Miyauchi Y; Mii Y; Morishita T; Miura S; Honoki K; Aoki M; Kido A; Tamai S; Hino M; Nomura Y; Nakanishi E
    Gan To Kagaku Ryoho; 1996 Apr; 23(5):595-9. PubMed ID: 8678518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Studies on high-dose methotrexate with citrovorum factor rescue therapy in children: analysis of bone marrow cell kinetics by flow cytometry].
    Tsurusawa M; Sasaki K; Matsuoka H; Katano N; Fujimoto T
    Gan To Kagaku Ryoho; 1985 Sep; 12(9):1827-32. PubMed ID: 3876075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose methotrexate: pharmacokinetics in children and young adults.
    Raude E; Oellerich M; Weinel P; Freund M; Schrappe M; Riehm H; Poliwoda H
    Int J Clin Pharmacol Ther Toxicol; 1988 Jul; 26(7):364-70. PubMed ID: 3209285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose methotrexate with leucovorin rescue in ovarian cancer: a phase II study.
    Parker LM; Griffiths CT; Yankee RA; Knapp RC; Canellos GP
    Cancer Treat Rep; 1979 Feb; 63(2):275-9. PubMed ID: 312692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate megadosage followed by folate rescue. I. A study in clearance patterns.
    Salasoo S; Irving MG; Lam-Po0Tang R; O'Gorman-Hughes D; Freedman A
    Med J Aust; 1976 May; 1(21):777-9. PubMed ID: 1085404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Studies on the effect of high-dose methotrexate-citrovorum factor treatment for 89Sr induced osteosarcoma in mice (author's transl)].
    Nakamura T
    Nihon Seikeigeka Gakkai Zasshi; 1982 Feb; 56(2):149-61. PubMed ID: 6978919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
    Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
    Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
    Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
    Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of high-dose methotrexate with citrovorum factor on human granulopoiesis.
    Schremi W; Lohrmann HP
    Cancer Res; 1979 Oct; 39(10):4195-9. PubMed ID: 314330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.